A single-institution chart review evaluating safety and efficacy of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP).
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2017 New trial record